• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
GAN Xia, NIAN Siyun, WANG Guoping. Advances in the development of farnesoid X receptor antagonists[J]. Journal of China Pharmaceutical University, 2016, 47(5): 521-530. DOI: 10.11665/j.issn.1000-5048.20160503
Citation: GAN Xia, NIAN Siyun, WANG Guoping. Advances in the development of farnesoid X receptor antagonists[J]. Journal of China Pharmaceutical University, 2016, 47(5): 521-530. DOI: 10.11665/j.issn.1000-5048.20160503
shu

Advances in the development of farnesoid X receptor antagonists

More Information
    Graphical Abstract
    • Abstract
  • Farnesoid X receptor(FXR), a member of the nuclear receptor superfamily, plays an important role on the regulating bile acid, lipid and glucose homeostasis. FXR antagonist can stimulate the conversion of total cholesterol into bile acid by improving the activity of CYP7A1. It can also reduce the content of triglyceride, low-density lipoprotein and increase that of high-density lipoprotein by regulating the relevant target genes. Considering the above facts, FXR antagonist is expected to become a potential drug to treat hyperlipidemia. In recent years, great progress has been made in the research on FXR antagonists with their various structural types having been obtained. This article introduces natural and synthetic FXR antagonists reported in recent years.
    • FullText(HTML)
    • References (34)
  • [1]
    Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites[J].Cell,1995,81(5):687-693.
    [2]
    Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids[J].Science,1999,284(5418):1362-1365.
    [3]
    Mazuy C,Helleboid A,Staels B,et al.Nuclear bile acid signaling through the farnesoid X receptor[J].Cell Mol Life Sci,2015,72(9):1631-1650.
    [4]
    Fiorucci S,Rizzo G,Donini A,et al.Targeting farnesoid X receptor for liver and metabolic disorders[J].Trends Mol Med, 2007,13(7):298-309.
    [5]
    Amano Y, Shimada M, Miura S, et al. Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates[J].Eur J Pharmacol,2014,723:108-115.
    [6]
    Urizar NL,Liverman AB,Dodds DT,et al.A natural product that lowers cholesterol as an antagonist ligand for FXR[J].Science,2002,296(5573):1703-1706.
    [7]
    Cui J, Huang L, Zhao A, et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump[J].J Biol Chem,2003,278(12):10214-10220.
    [8]
    Burris TP,Montrose C,Houck KA,et al.The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand[J].Mol Pharmacol,2005,67(3):948-954.
    [9]
    Carter BA,Taylor OA,Prendergast DR,et al.Stigmasterol,a soy lipid-derived phytosterol,is an antagonist of the bile acid nuclear receptor FXR[J].Pediatr Res,2007,62(3):301-306.
    [10]
    De Marino S,Ummarino R,D′Auria MV,et al.Theonellasterols and conicasterols from Theonella swinhoei.Novel marine natural ligands for human nuclear receptors[J].J Med Chem,2011,54(8):3065-3075.
    [11]
    Sepe V,Bifulco G,Renga B,et al.Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor[J].J Med Chem, 2011,54(5):1314-1320.
    [12]
    Putra MY,Bavestrello G,Cerrano C,et al.Polyhydroxylated sterols from the Indonesian soft coral Sinularia sp.and their effect on farnesoid X-activated receptor[J].Steroids,2012,77(5):433-440.
    [13]
    Kumar D,Khanna AK,Pratap R,et al.Dose escalation pharmacokinetics and lipid lowering activity of a novel farnesoid X receptor modulator:16-dehydropregnenolone[J].Indian J Pharmacol,2012,44(1):57-62.
    [14]
    Nam SJ, Ko H, Shin M, et al. Farnesoid X-activated receptor antagonists from a marine sponge Spongia sp.[J].Bioorg Med Chem Lett,2006,16(20):5398-5402.
    [15]
    Nam SJ, Ko H, Ju MK, et al. Scalarane sesterterpenes from a marine sponge of the genus Spongia and their FXR antagonistic activity[J].J Nat Prod,2007,70(11):1691-1695.
    [16]
    Choi H,Hwang H,Chin J,et al.Tuberatolides,potent FXR antagonists from the Korean marine tunicate Botryllus tuberatus[J].J Nat Prod,2011,74(1):90-94.
    [17]
    Di Leva FS,Festa C,D′Amore C,et al.Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors.design,synthesis,and biological evaluation of novel ligands[J].J Med Chem,2013,56(11):4701-4717.
    [18]
    Dussault I,Beard R,Lin M,et al.Identification of gene-selective modulators of the bile acid receptor FXR[J].J Biol Chem,2003,278(9):7027-7033.
    [19]
    Kainuma M,Makishima M,Hashimoto Y,et al.Design,synthesis,and evaluation of non-steroidal farnesoid X receptor(FXR)antagonist[J].Bioorg Med Chem,2007,15(7):2587-2600.
    [20]
    Huang H,Yu Y,Gao Z,et al.Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel,potent,and nonsteroidal farnesoid X receptor(FXR)selective antagonists[J].J Med Chem,2012,55(16):7037-7053.
    [21]
    Ma RQ.The design,synthesis and biological evaluation of FXR antagnists and the research on microwave-assisted one-pot synthesis of 4-arylidene-pyrazolone derivatives( FXR拮抗剂的设计、合成与药理活性研究及4-芳亚甲基取代吡唑酮类衍生物的方法学研究)[D].Shanghai:East China University of Science and Technology,2011.
    [22]
    Yu DD,Lin W,Forman BM,et al.Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor[J].Bioorg Med Chem,2014,22(11):2919-2938.
    [23]
    Huang H,Si P,Wang L,et al.Design,synthesis,and biological evaluation of novel nonsteroidal farnesoid X Receptor(FXR)antagonists:molecular basis of FXR antagonism[J].Chem Med Chem,2015,10(7):1184-1199..
    [24]
    Amano Y,Ishikawa E,Shinozawa E,et al.Combinational effects of farnesoid X receptor antagonist and statin on plasma lipid levels and low-density lipoprotein clearance in guinea pigs[J].Life Sci,2014,108(1):7-12.
    [25]
    Liu P,Xu X,Chen L,et al.Discovery and SAR study of hydroxyacetophenone derivatives as potent,non-steroidal farnesoid X receptor(FXR)antagonists[J].Bioorg Med Chem Lett,2014,22(5):1596-1607.
    [26]
    Liu P.The design,synthesis and SAR studies of two types of FXR antagonists and the exploring of aryne in several reactions(两类FXR拮抗剂的设计、合成与构效关系研究及芳炔参与的反应研究)[D].Shanghai:East China University of Science and Technology,2014.
    [27]
    Xu X,Xu X,Liu P,et al.Structural basis for small molecule NDB(N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino)benzamide)as a selective antagonist of farnesoid X receptor α(FXRα)in stabilizing the homodimerization of the receptor[J].J Biol Chem,2015,290(32):19888-19899.
    [28]
    Merk D,Lamers C,Ahmad K,et al.Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators:development of a highly potent partial farnesoid X receptor agonist[J].J Med Chem,2014,57(19):8035-8055.
    [29]
    Fu J,Si P,Zheng M,et al.Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking[J].Bioorg Med Chem Lett,2012,22(22):6848-6853.
    [30]
    Wang L,Si P,Sheng Y,et al.Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening[J].Chem Biol Drug Des, 2015,85(4):481-487.
    [31]
    Liu Z, Law WK, Wang D, et al. Synthesis and discovery of andrographolide derivatives as non-steroidal farnesoid X receptor(FXR)antagonists[J].RSC Adv,2014,4(26):13533-13545.
    [32]
    Kaimal R,Song X,Yan B,et al.Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones[J].J Pharmacol Exp Ther,2009,330(1):125-134.
    [33]
    Lu W,Cheng F,Jiang J,et al.FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach[J].Sci Rep,2015,5:8114.
    [34]
    Schmidt J, Klingler FM, Proschak E, et al. NSAIDs Ibuprofen,indometacin,and diclofenac do not interact with farnesoid X receptor[J].Sci Rep,2015,5:14782.
    • Related Articles

  • Related Articles

    [1]YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
    [2]LI Yin, GU Hongfeng, ZOU Yi, WANG Shuping, XU Yungen. Research progress of mono-(ADP-ribosyl) transferase family and their inhibitors in tumor therapy[J]. Journal of China Pharmaceutical University, 2021, 52(6): 643-652. DOI: 10.11665/j.issn.1000-5048.20210601
    [3]BU Hong, ZHOU Jinpei, ZHANG Huibin. Research progress of mitogen-activated protein kinase interacting kinases inhibitors in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2021, 52(4): 410-421. DOI: 10.11665/j.issn.1000-5048.20210403
    [4]FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
    [5]TIAN Jiping, ZHANG Jian, ZHOU Jinpei, ZHANG Huibin. Advances in small molecule inhibitors of PD-1/PD-L1 immune checkpoint pathway[J]. Journal of China Pharmaceutical University, 2019, 50(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20190101
    [6]LIU Kejun, ZHANG Zhimin, RAN Ting, CHEN Hongli, LU Tao, CHEN Yadong. Advances in BET bromodomain protein inhibitors[J]. Journal of China Pharmaceutical University, 2015, 46(3): 264-271. DOI: 10.11665/j.issn.1000-5048.20150302
    [7]ZHANG Yuan, CHENG Yulan, ZHOU Jinpei, ZHANG Huibin. Advances on receptor tyrosine kinase inhibitors taking c-Met as anti-tumor target[J]. Journal of China Pharmaceutical University, 2015, 46(1): 16-27. DOI: 10.11665/j.issn.1000-5048.20150102
    [8]LI Chunhong, DU Hongjin, WEN Xiao′an, SUN Hongbin. Advances in inhibitors of MDM2 and MDM4[J]. Journal of China Pharmaceutical University, 2015, 46(1): 1-15. DOI: 10.11665/j.issn.1000-5048.20150101
    [9]DENG Lian-bai, LI Ai-xiu, JIN Yu-rui. Advances in the study on inhibitors of RNase H,a novel anti-HIV drug target[J]. Journal of China Pharmaceutical University, 2011, 42(6): 578-584.
    [10]KONG Kai-lai, LU Shuai, GAO Yi-ping, YANG Pei, TANG Wei-fang, LU Tao. Advances on the study of PLK1 inhibitors as antitumor agents[J]. Journal of China Pharmaceutical University, 2011, 42(1): 9-15.

  • Cited by

    Periodical cited type(2)

    1. 郁莉，蒋颖敏，许磊，朱景宇. 分子对接与分子动力学模拟法探究PI3Kδ/度维利塞(Duvelisib)的选择性结合. 化学研究与应用. 2022(02): 341-348 .
    2. 蔡燕飞，陈蕴，史劲松，金坚. 抗肿瘤药物体外药效学评价结合细胞生物学实验教学促进教研融合. 实验室研究与探索. 2020(08): 192-195 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (1068) PDF downloads (3646) Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：285535

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return